Article citationsMore>>

Ntukidem N, Arce-Lara C, Otterson GA, Kraut E, Cataland S, Bekaii-Saab T. Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. Cancer Chemother Pharmacol 2009 Jun 9.

has been cited by the following article:

• TITLE: Thrombotic Microangiopathy Induced by Hyperthermal Intraperitoneal Chemotherapy with Mitomycin C

  AUTHORS: Mahir Köksal, Robert J van Ginkel, Jan G Zijlstra

  KEYWORDS: HIPEC, Toxicity, HUS-TTP

  JOURNAL NAME: Surgical Science, Vol.2 No.4, June 23, 2011

  ABSTRACT: A patient with pseudomyxoma peritonei underwent Hyperthermal Intraperitoneal Chemotherapy (HIPEC) with Mitomycin C after which she developed thrombotic microangiopathy. This syndrome mimicked possi-ble surgical complications. Treatment with plasma exchange resolved the syndrome and the patient recov-ered completely. This is the first description of thrombotic microangiopathy early after a single dose intrap-eritoneal Mitomycin C.